RxDoctor Payments Data

Robert Rosentreter

Family · Fairbanks, AKNPI 1780340851

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 29.2% of the total. Reporting peaked in 2022 at $1,208 and has fallen 81.7% since, to $221 in 2025.

$2,337in general payments, 2019–2025

Across 97 payments — averaging $24.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$683
  • AstraZeneca$408
  • Novo Nordisk$218
  • Biohaven Pharmaceutical Holding Company Ltd.$212
  • GSK$171
  • Lilly USA, LLC$89
  • plus $555 from 14 others

What the payments were for

  • Food & beverage$2,337100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,337 in reported general payments places this provider in the 85th percentile of 315 family providers in Alaska.

See all family providers in Alaska

Other family in Fairbanks

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →